Facilitating the Learning Experience During and After Cancer Treatment
Staying Connected is a FREE professional education program for schoolteachers, nurses, social workers, guidance counselors, college faculty, administrators and interested parents. The goal of this program is to educate participants on the effects of childhood, adolescent, and young adult cancer treatment to improve the learning experience during and after cancer treatment.
The program objectives are to teach participants how to:
==============================================
Continuing Education Information:
Upon completion of this program and submission of the activity evaluation, a certificate of completion for 3.0 continuing Education hours will be issued at the conclusion of the program.
Target Audience: Intermediate and Advanced Level Nurses and Social Workers, and School Personnel
Approval for nurses has been obtained by The Leukemia & Lymphoma Society's national office under Provider Number CEP 5832 to award 3.0 continuing education contact hours through the California Board of Registered Nursing.
Social workers should contact their regulatory board to determine course approval. Social workers will receive 3.0 CE clinical clock hours.
The Leukemia & Lymphoma Society (LLS), Provider Number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) (www.aswb.org) Approved Continuing Education Program (CE). Approval Period: 12/2011-12/2014. LLS maintains responsibility for the program.
===============================================
For additional information on the Tennessee Chapter's educational programs and/or financial assistance, contact Patient Services Manager Mary Winslow, LCSW, at mary.winslow@lls.org, (615) 331.2980 or (800) 332.2980, extension 1743.
Topics include current and emerging therapies, patient-provider communications, issues for people living with myeloma and more.
Topics include current and emerging therapies, patient-provider communications, issues for people living with myeloma and more.
Topics include PTCL and PTCL subtypes, treatment options, the role of clinical trials and patient-provider communications.